Annika Osswald Selected Research

BI 1002494

4/2020

Inhibition of SYK kinase does not confer a pro-proliferative or pro-invasive phenotype in breast epithelium or breast cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Annika Osswald Research Topics

Disease

4	Neoplasms (Cancer) 01/2019 - 01/2015
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2022 - 01/2022
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 11/2022
1	Carcinogenesis 01/2022
1	Inflammation (Inflammations) 01/2022
1	Colorectal Neoplasms (Colorectal Cancer) 01/2022
1	Breast Neoplasms (Breast Cancer) 04/2020
1	Colonic Neoplasms (Colon Cancer) 01/2019
1	Adenocarcinoma 12/2015

Drug/Important Bio-Agent (IBA)

3	BI 836858IBA 12/2022 - 01/2022
2	Monoclonal AntibodiesIBA 12/2022 - 01/2022
1	Decitabine FDA Link 12/2022
1	Bile Acids and Salts (Bile Acids)IBA 01/2022
1	Bile Pigments (Bilin)IBA 01/2022
1	BilirubinIBA 01/2022
1	VimentinIBA 04/2020
1	Syk KinaseIBA 04/2020
1	Proliferating Cell Nuclear Antigen (PCNA)IBA 04/2020
1	BI 1002494IBA 04/2020
1	SodiumIBA 01/2019
1	IndazolesIBA 01/2019
1	RutheniumIBA 01/2019
1	KP 1339IBA 01/2019
1	Adenosine Triphosphate (ATP)IBA 01/2019
1	CalreticulinIBA 01/2019
1	PlasticsIBA 01/2016
1	ProdrugsIBA 12/2015
1	Cytosine DeaminaseIBA 01/2015
1	Flucytosine (Ancobon)FDA Link 01/2015
1	Fluorouracil (Carac)FDA LinkGeneric 01/2015

Therapy/Procedure

1	Enzyme Therapy 12/2015
1	Therapeutics 12/2015